Wednesday, August 31, 2016 4:45:44 PM
Either Seymour is lying here, or he was lying to the investing public when he presented that schedule in Jan 2016:
"Since the end of June marks the end of our fiscal year, this is an opportunity to write a CEO letter that addresses these concerns.
Unfortunately, most non-scientists don’t understand the complexity of the outside testing process. This is not like a pathology lab where you send in a sample for analysis, the sample is tested using a standard protocol and the results are sent back quickly. Our staff has the equipment and the knowledge to do this testing but you always want independent analysis. In the future, as we do this multiple times with different drugs, the universities will have developed their own verifiable and reproducible protocols
All of our new hires receive months of training, no matter what their background is. We have to help educate the university scientists.
Our university and commercial collaborators need our help in setting up their testing protocols. They have to run multiple positive and negative controls to verify that their results will be reproducible. Then they run the samples multiple times. An animal protocol has to be developed, tested, verified and then run again looking for consistent results.
Nanotechnology is generally new to these universities, especially working with polymeric nanomicelles. We have 25 years of experience. We also have millions of dollars of specialized testing equipment that lets us do very sophisticated analysis. Unfortunately, the universities don’t have this equipment!
That’s why it's taking so long"
A casual stroll through the lunatic asylum shows that faith does not prove anything. Friedrich Nietzsche
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
- NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City • GlobeNewswire Inc. • 05/04/2023 10:45:00 AM
FEATURED Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • Apr 22, 2024 8:49 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM